早期不响应新辅助化疗会增加宫癌的复发:系统性审查
Shiqing Huang1,2, Runfeng Yang3, Li Yang1,2
1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
早期对新辅助化疗 (NACT) 的不反应显著预测了宫癌患者的无病生存率 (DFS) 的下降. 这一发现凸显了对不响应患者的最佳治疗策略的需要.
科学领域:
- 妇科瘤学
- 医疗瘤学
- 临床研究
背景情况:
- 宫癌对全球女性来说是一个重大的健康挑战.
- 新辅助化疗 (NACT) 是一种新兴的治疗选择,但其预后影响,特别是早期不反应,需要进一步阐明.
研究的目的:
- 在宫癌患者中,系统地审查和阐明NACT早期不反应与长期无病生存率 (DFS) 之间的关联.
主要方法:
- 根据PRISMA指南进行了全面的系统审查.
- 搜索包括PubMed,Embase,Elsevier,Springer,EBSCO和科克兰图书馆.
- 使用R软件计算了DFS的聚合危险比率 (HRs),使用已知的统计方法评估异质性和出版偏差.
主要成果:
- 包括2064名患者 (1546名反应者,518名不反应者) 的11项研究.
- 早期没有对NACT的反应与较差的DFS相关 (HR=3.29,95%CI为2.35- 4.62).
- 根据响应标准 (WHO和RECIST) 的小组分析证实了这一关联,没有发现显著的出版偏差.
结论:
- 早期对NACT无反应是宫癌中DFS恶化的重要预测因素.
- 结果表明需要进行大规模或前性研究来验证这种预后价值,并优化非响应患者的治疗策略.
- 未来的前性试验对于验证结果和建立基于NACT的患者选择标准至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
